Back to School: How biopharma can reboot drug development. Access exclusive analysis here

DNA-based vaccine with genes coding for two HIV proteins: Began a Phase I/II trial of safety in 15 people who will receive an initial injection at one of three

Apollon Inc., Malvern, Penn.
Product: DNA-based vaccine

Read the full 72 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE